Drugs / CsA-PG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06942793 | May → Oct 2025 overdue | dry eye syndrome | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CsA-PG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06942793 ↗ |
| Route | Other | “Administer to eyes” NCT06942793 ↗ |